ASCO 2024 Annual Meeting

The American Society of Clinical Oncology's (ASCO) 2024 Annual Meeting will be held May 31 – June 4, 2024, both in-person in Chicago, IL, and virtually. Thousands of oncology professionals from around the world will attend ASCO 2024, which provides updates on new clinical advances in every area of cancer research and strives to advance equitable cancer care through international innovation. This year's theme is The Art and Science of Cancer Care: From Comfort to Cure and will feature more than 200 sessions and 5,000 abstracts.

See the full program »

The Mass General Cancer Center will have a strong presence at ASCO 2024, with dozens of leaders sharing their latest research in abstract presentations, poster sessions, discussions and more.

Friday, May 31, 2024

Striking the Balance With Next-Generation Targeted Therapies for ALK and EGFR
4:21 p.m. - 4:33 p.m. in Arie Crown Theater
Discussant: Jessica Lin, MD

Multi-site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-intensive Therapy
5:09 p.m. - 5:21 p.m. in S100bc
Late Breaker Oral Presentation: Areej El-Jawahri, MD

Saturday, June 1, 2024

The Acceptability of Hospital-at-Home for Persons Living With Cancer and Their Caregivers
9:00 a.m. in Hall A
Poster: Daniel E. Lage, MD, MSc

Deep Learning vs Traditional Breast Cancer Risk Assessment Models: Are We Offering Supplemental Services to Those Who Benefit the Most?
9:00 a.m. in Hall A
Poster: Leslie Lamb, MD, MSc

CDKN2A Deletion and Radiation Sensitivity in IDH-mutant Astrocytomas
9:00 a.m. in Hall A
Poster: Logan Muzyka, BS

RNA-based Fusion Testing in Gastrointestinal (GI) Carcinomas: A Single-Institution Experience
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Bennett Caughey, MD

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Samuel J. Klempner, MD

A Phase 1, Open-label, Dose Escalation Study on the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Jong Chul Park, MD

Association of Single Nucleotide Polymorphisms (SNPs) in Inflammatory Pathways With Breast Cancer (BC) Risk: A Multi-ethnic Scoping Review
9:00 a.m. in Hall A
Poster: Erina Quinn, DO

Discussing Goals of Care: When Prognosis May Be Shorter, Longer, or Uncertain
1:30 p.m. in E450a
Poster: Jennifer Shin, MD, MPH

Use of Baseline and Serial ctDNA Dynamics to Predict Outcomes in Patients Treated With First-line Tebentafusp, Including Those Who Were and Were Not Treated Beyond Progression
1:30 p.m. in Hall A
Poster: Ryan Sullivan, MD

Efficacy and Safety of Lurbinectedin (LUR) With Irinotecan (IRI) in a Phase 2 Expansion Cohort of Patients (Pts) With Synovial Sarcoma (SS)
1:30 p.m. - 4:30 p.m. in Hall A
Poster: Gregory Cote, MD, PhD, MS

Randomized Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
1:30 p.m. - 4:30 p.m. in Hall A
Poster: Gregory Cote, MD, PhD, MS

CYCLONE 2: A Phase 3 Study of Abemaciclib With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer
3:12 p.m. - 3:24 p.m. in Arie Crown Theater
Oral Presentation: Matthew Smith, MD, PhD

First-line Inavolisib/Placebo + Palbociclib + Fulvestrant (Inavo/Pbo+Palbo+Fulv) in Patients (Pts) With PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced/Metastatic Breast Cancer Who Relapsed During/Within 12 Months (Mo) of Adjuvant Endocrine Therapy Completion: INAVO120 Phase III Randomized Trial Additional Analyses
3:24 p.m. in Hall B1 and Live Stream
Oral Presentation: Dejan Juric, MD

Circulating Tumor DNA: Current Practices and Future Directions
4:45 p.m. in Hall D2
Chair: Priyadarshini Pathak, MBBS

Pan-tumor Activity of Olomorasib (LY3537982), a Second-generation KRAS G12C Inhibitor (G12Ci), in Patients With KRAS G12C-mutant Advanced Solid Tumors
5:00 p.m. - 5:12 p.m. in Hall D1
Oral Presentation: Rebecca Heist, MD, MPH

Sunday, June 2, 2024

Multi-site Randomized Trial of Stepped Palliative Care (PC) for Patients With Advanced Lung Cancer
8:00 a.m. - 8:12 a.m. in S100a and Live Stream
Oral Presentation: Jennifer S. Temel, MD, FASCO

Randomized Trial of a Multimodal Intervention to Enhance Sexual Function and Quality of Life (QOL) in Hematopoietic Stem Cell Transplant (HSCT) Survivors
9:00 a.m. - 9:12 a.m. in S100a and Live Stream
Oral Presentation: Areej El-Jawahri, MD

Sequential Combination of Sacituzumab Govitecan and Talazoparib in Metastatic Triple Negative Breast Cancer (mTNBC): Results From a Phase II Study
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Rachel Occhiogrosso Abelman, MD

BLU-222, an Investigational, Oral, Potent, and Highly Selective CDK2 Inhibitor (CDK2i), as Monotherapy in Patients (Pts) With Advanced Solid Tumors and in Combination With Ribociclib (RIBO) and Fulvestrant (FUL) in HR+/HER2− Breast Cancer (BC)
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Dejan Juric, MD

INAVO121: Phase III Study of Inavolisib (INAVO) + Fulvestrant (FUL) vs. Alpelisib (ALP) + FUL in Patients (Pts) With Hormone Receptor-positive, HER2-negative (HR+, HER2–), PIK3CA-mutated (mut) Locally Advanced or Metastatic Breast Cancer (LA/mBC)
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Dejan Juric, MD

Nectin-4 Expression in Primary Breast Cancer and Associated Clinical Outcomes
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Arielle Medford, MD

Immune Related Adverse Events in Patients With Breast Cancer and Autoimmune Disease Treated With Immunotherapy
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Neelima Vidula, MD

Phase II Study of a PARP Inhibitor, Talazoparib, in HER2- metastatic Breast Cancer (MBC) With a Somatic BRCA1/2 Mutation Identified in a Cell-free DNA or Tumor Tissue Genotyping Assay
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Neelima Vidula, MD

Interim Analysis (IA) of the Giredestrant (G) + Everolimus (EVERO) Arm in MORPHEUS Breast Cancer (BC): A Phase I/II Study of G Treatment (tx) Combinations in Patients (Pts) With Estrogen Receptor-positive (ER+), HER2-negative, Locally Advanced/Metastatic BC (LA/mBC)
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Seth Wander, MD, PhD

What New Therapies for “Undruggable Targets” Are on the Horizon?
10:25 a.m. in E450a
Oral Presentation: Keith Flaherty, MD

Comparative Effectiveness Trial of Early Palliative Care Delivered via Telehealth Versus in Person Among Patients With Advanced Lung Cancer
2:13 p.m. in Hall B1
Oral Abstract - Plenary Session: Joseph A. Greer, PhD, and Jennifer S. Temel, MD, FASCO

Discussion of LBA4
2:59 p.m. in Hall B1
Plenary Session: Lecia Sequist, MD, MPH

Randomized Phase II/III Study of R-CHOP +/- Venetoclax in Previously Untreated MYC/BCL2 Double Expressor Diffuse Large B Cell Lymphoma (DLBCL): Alliance A051701
5:00 p.m. - 5:06 p.m. in E450b
Rapid Oral Presentation: Jeremy Abramson, MD

Monday, June 3, 2024

Alliance A071401: Phase II Trial of Abemaciclib in Patients With Grade 2/3 Meningiomas Harboring Somatic NF2 or CDK Pathway Alterations
8:12 a.m. - 8:24 a.m. in S100bc
Oral Presentation: Priscilla Brastianos, MD

Trajectories of Patient-Reported Outcomes After Prolonged Stays for Hematopoietic Cell Transplant
9:00 a.m. in Hall A
Poster: Lucy Gao, MD

Rapid Reduction of Free Light Chains and Improvement in Renal Outcomes in Patients With Newly Diagnosed Multiple Myeloma Admitted With Acute Kidney Injury With Daratumumab-based Therapy and Without Plasmapheresis
9:00 a.m. in Hall A
Poster: E. Bridget Kim, BCOP, PharmD

Effect of Multi-cancer Early Detection Screening on Late-stage Cancers: A Modeling Study
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Jagpreet Chhatwal, PhD

Impact of Clinical Response and AEs on Health-related Quality of Life (HRQoL) in Patients (Pts) With R/R Large B-cell Lymphoma (LBCL): Pooled Data From 4 Lisocabtagene Maraleucel (Liso-Cel) Trials
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Patrick Johnson, MD

Post-acute Care Facility Utilization and Outcomes Among Medicare Beneficiaries Undergoing Inpatient Cancer Surgery
9:00 a.m. - 12:00 p.m. in Hall A
Poster: Daniel E. Lage, MD, MSc

Assessing the Risk of Uterine Serous Carcinoma in Survivors of Triple-negative Breast Cancer: Is BRCA1 the Link?
9:00 a.m. - 12:00 p.m. in Hall A
Poster: William Manning, MD

Understanding the Evidence: Can Palliative Care and Hematologic Malignancies Coexist?
11:45 a.m. in E350
Chair: Areej El-Jawahri, MD

Risk of Secondary Leukemias in Patients With Germline PALB2 Pathogenic Variants After Chemotherapy Exposure
1:30 p.m. in Hall A
Poster: Hatem Ellaithy, MD

Coping in Caregivers of Patients With Primary Malignant Brain Tumors: A Mediation Analysis of a Randomized Controlled Trial
1:30 p.m. - 4:30 p.m. in Hall A
Poster: Deborah Forst, MD

Updated Results From ERAS-007 Plus Encorafenib and Cetuximab (EC) in Patients (Pts) With EC-naïve Metastatic BRAF V600E Colorectal Cancer (CRC) in the Phase 1b/2 HERKULES-3 Study
2:27 p.m. - 2:33 p.m. in Arie Crown Theater
Rapid Oral Presentation: Aparna Parikh, MD

Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development and the Role of the Tumor Microenvironment
3:00 p.m. in Hall D2 and Live Stream
Moderator: Aparna Raj Parikh, MD

Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study
5:06 p.m. - 5:18 p.m. in S100a
Clinical Science Symposium: Mary Catherine Boulanger, MD

Circulating Biomarkers: Waiting for a MIRACLE
5:30 p.m. in Hall D2
Clinical Science Symposium: Ryan Corcoran, MD, PhD